Barclays PLC decreased its holdings in BiomX Inc. (NYSEMKT:PHGE – Free Report) by 90.0% in the third quarter, Holdings Channel reports. The fund owned 25,000 shares of the company’s stock after selling 225,000 shares during the quarter. Barclays PLC’s holdings in BiomX were worth $26,000 at the end of the most recent quarter.
Separately, Ikarian Capital LLC bought a new stake in BiomX in the third quarter worth about $911,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.
BiomX Price Performance
Shares of NYSEMKT PHGE opened at $0.76 on Friday. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $13.86 million, a P/E ratio of -1.02 and a beta of 1.26. The stock has a 50-day moving average price of $0.66 and a 200-day moving average price of $1.34.
About BiomX
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Further Reading
- Five stocks we like better than BiomX
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Monster Growth Stocks to Buy Now
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Want to see what other hedge funds are holding PHGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BiomX Inc. (NYSEMKT:PHGE – Free Report).
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
